dostęp płatny
Rola mikrobioty jelitowej w patofizjologii i profilaktyce różnych schorzeń układu pokarmowego


- Zakład Endoskopii, Szpital Uniwersytecki w Krakowie Klinika Chorób Wewnętrznych i Geriatrii,Collegium Medicum UJ w Krakowie, ul. Jakubowskiego 2, 30-688 Kraków, Polska
dostęp płatny
Streszczenie
Streszczenie
Pełny tekst:
Dodaj do koszyka: 15,00 PLN
Słowa kluczowe
mikrobiota, probiotyk, prebiotyk, bariera jelitowa, dysbioza, eubioza


Tytuł
Rola mikrobioty jelitowej w patofizjologii i profilaktyce różnych schorzeń układu pokarmowego
Czasopismo
Numer
Strony
73-87
Opublikowany online
2020-04-02
Wyświetlenia strony
524
Wyświetlenia/pobrania artykułu
47
Rekord bibliograficzny
Forum Medycyny Rodzinnej 2020;14(2):73-87.
Słowa kluczowe
mikrobiota
probiotyk
prebiotyk
bariera jelitowa
dysbioza
eubioza
Autorzy
Michał Kukla


- Lilly DM, Stillwell RH. Probiotics: Growth-Promoting Factors Produced by Microorganisms. Science. 1965; 147(3659): 747–748.
- Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics--approaching a definition. Am J Clin Nutr. 2001; 73(2 Suppl): 361S–364S.
- Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125(6): 1401–1412.
- Lederberg J, McCray AT. Ome sweet 'omics – a genealogical treasury of words. The Scientist. 2001; 15(7): 8.
- Whiteside SA, Razvi H, Dave S, et al. The microbiome of the urinary tract--a role beyond infection. Nat Rev Urol. 2015; 12(2): 81–90.
- Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, et al. Probiotic mechanisms of action. Ann Nutr Metab. 2012; 61(2): 160–174.
- Plaza-Díaz J, Ruiz-Ojeda FJ, Gil-Campos M, et al. Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases. Nutrients. 2018; 10(1).
- Yadav AK, Tyagi A, Kumar A, et al. Adhesion of lactobacilli and their antiinfectivity potential. Crit Rev Food Sci Nutr. 2017; 57: 2042–2056.
- Van Tassell ML, Miller MJ. Lactobacillus adhesion to mucus. Nutrients. 2011; 3(5): 613–636.
- Buck BL, Altermann E, Svingerud T, et al. Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM. Appl Environ Microbiol. 2005; 71(12): 8344–8351.
- Collado M, Gueimonde M, Salminen S. Probiotics in Adhesion of Pathogens. Bioactive Foods in Promoting Health. 2010: 353–370.
- Hardy H, Harris J, Lyon E, et al. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients. 2013; 5(6): 1869–1912.
- Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes. 2010; 1(3): 148–163.
- Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006; 130(3): 731–746.
- Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes. 2010; 1(3): 148–163.
- Viladomiu M, Hontecillas R, Yuan L, et al. Nutritional protective mechanisms against gut inflammation. J Nutr Biochem. 2013; 24(6): 929–939.
- Hsieh FC, Lee CL, Chai CY, et al. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab (Lond). 2013; 10(1): 35.
- Rizzello V, Bonaccorsi I, Dongarrà ML, et al. Role of natural killer and dendritic cell crosstalk in immunomodulation by commensal bacteria probiotics. J Biomed Biotechnol. 2011; 2011: 473097.
- Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes. 2010; 1(3): 148–163.
- Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2010; 298(6): G807–G819.
- Kulkarni N, Reddy BS. Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc Soc Exp Biol Med. 1994; 207(3): 278–283.
- Pavlović N, Stankov K, Mikov M. Probiotics--interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 2012; 168(7): 1880–1895.
- Grąt M, Wronka KM, Lewandowski Z, et al. Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017; 36(6): 1530–1539.
- Food and Agriculture Organization/World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina: American Cordoba Park Hotel. Rome, Italy: FAO/WHO 2001.
- Pavlović N, Stankov K, Mikov M. Probiotics — interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 2012; 168(7): 1880–1895.
- Kumar R, Grover S, Batish VK. Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing Lactobacillus plantarum strains in Sprague-Dawley rats. Br J Nutr. 2011; 105(4): 561–573.
- Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. Am J Gastroenterol. 2016; 111(5): 602–622.
- https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf.
- Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(23): 7381–7391.
- Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012; 307(18): 1959–1969.
- Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015; 42(7): 793–801.
- Cimperman L, Bayless G, Best K, et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol. 2011; 45(9): 785–789.
- Ouwehand AC, DongLian C, Weijian Xu, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014; 32(4): 458–463.
- Koning CJM, Jonkers DM, Stobberingh EE, et al. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am J Gastroenterol. 2008; 103(1): 178–189.
- Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis. 2012; 16(11): e786–e792.
- Goldenberg JZ, Ma SSY, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013(5): CD006095.
- Lahtinen SJ, Forssten S, Aakko J, et al. Probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM® modifies subpopulations of fecal lactobacilli and Clostridium difficile in the elderly. Age (Dordr). 2012; 34(1): 133–143.
- Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004; 7(1): 59–62.
- Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005; 3(5): 442–448.
- Dang Y, Reinhardt JD, Zhou X, et al. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014; 9(11): e111030.
- Hauser G, Salkic N, Vukelic K, et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2015; 94(17): e685.
- Ojetti V, Bruno G, Ainora ME, et al. Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol Res Pract. 2012; 2012: 740381.
- Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter. 2012; 17(4): 254–263.
- Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012; 18(43): 6302–6307.
- Bekar O, Yilmaz Y, Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food. 2011; 14(4): 344–347.
- Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25(2): 155–168.
- Francavilla R, Polimeno L, Demichina A, et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol. 2014; 48(5): 407–413.
- Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol. 2014; 7(1): 4–13.
- Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2013; 38(7): 741–751.
- Lahner E, Esposito G, Zullo A, et al. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol. 2012; 18(41): 5918–5924.
- Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011; 33(10): 1123–1132.
- Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30): 4012–4018.
- Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014; 109(10): 1547–61; quiz 1546, 1562.
- Sisson G, Ayis S, Sherwood RA, et al. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Aliment Pharmacol Ther. 2014; 40(1): 51–62.
- Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014; 7(3): 156–163.
- Jafari E, Vahedi H, Merat S, et al. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med. 2014; 17(7): 466–470.
- Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011; 45(8): 679–683.
- Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101(7): 1581–1590.
- Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59(3): 325–332.
- Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007; 26(3): 475–486.
- Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2009; 29(1): 104–114.
- Sinn DH, Song JiH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008; 53(10): 2714–2718.
- Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008; 27(1): 48–57.
- Paineau D, Payen F, Panserieu S, et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008; 99(2): 311–318.
- Silk DBA, Davis A, Vulevic J, et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009; 29(5): 508–518.
- Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009; 31(10): 655–659.
- Lorenzo-Zúñiga V, Llop E, Suárez C, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014; 20(26): 8709–8716.
- Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016(5): CD003044.
- Lunia MK, Sharma BC, Sharma P, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol. 2014; 12(6): 1003–8.e1.
- Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012; 107(7): 1043–1050.
- Zhao LN, Yu T, Lan SY, et al. Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis. Clin Res Hepatol Gastroenterol. 2015; 39(6): 674–682.
- Shukla S, Shukla A, Mehboob S, et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2011; 33(6): 662–671.
- Nabavi S, Rafraf M, Somi MH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014; 97(12): 7386–7393.
- Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99(3): 535–542.
- Shavakhi A, Minakari M, Firouzian H, et al. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med. 2013; 4(5): 531–537.
- Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9): 1090–1095.
- Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012; 57(2): 545–553.
- Szajewska H, Canani RB, Guarino A, et al. ESPGHAN Working Group for ProbioticsPrebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016; 62(3): 495–506.
- Malfertheiner P, Mégraud F, OʼMorain C, et al. Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. European Journal of Gastroenterology & Hepatology. 1997; 9(1): 1–2.
- Gross V. Aminosalicylates. Dig Dis. 2012; 30(1): 92–99.
- Dahl WJ, Stewart ML. Position of the Academy of Nutrition and Dietetics: Health Implications of Dietary Fiber. J Acad Nutr Diet. 2015; 115(11): 1861–1870.
- Krokowicz L, Stojcev Z, Kaczmarek BF, et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study. Int J Colorectal Dis. 2014; 29(3): 387–393.
- Riggio O, Varriale M, Testore GP, et al. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. J Clin Gastroenterol. 1990; 12(4): 433–436.
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–1402.
- Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014; 14(9): 581–597.
- Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019; 5(1): 1–10.